https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48714 Wed 29 Mar 2023 17:10:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48718 Wed 29 Mar 2023 16:01:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43676 Wed 28 Sep 2022 08:09:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53093 Wed 28 Feb 2024 16:21:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50124 Wed 28 Feb 2024 16:17:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51026 Wed 28 Feb 2024 16:13:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53765 Wed 28 Feb 2024 15:59:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49984 Wed 28 Feb 2024 15:55:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51883 Wed 28 Feb 2024 15:48:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51366 Wed 28 Feb 2024 15:46:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53918 Wed 28 Feb 2024 15:40:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53799 Wed 28 Feb 2024 15:24:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54338 Wed 28 Feb 2024 15:14:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40357 Wed 27 Jul 2022 15:15:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55374 Wed 22 May 2024 15:07:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45438 Wed 20 Mar 2024 15:45:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54898 Wed 20 Mar 2024 13:32:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54592 Wed 15 May 2024 09:23:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45437 Wed 13 Mar 2024 08:08:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47060 Wed 13 Mar 2024 08:04:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43927 n = 157) and without (n = 79) asthma. Mothers with asthma participated in this study following participation in a randomized controlled trial of a novel asthma management strategy during pregnancy. Mothers completed the Parenting Stress Index Short Form during the first 12 months postpartum. Mothers with asthma also completed the Asthma Control Questionnaire. Results: Parenting stress did not differ between mothers with and without asthma. Additionally, for mothers with asthma, there were no differences in levels of parenting stress based on asthma control. Conclusions: This study suggests that mothers with asthma are not at an increased risk for excessive parenting stress. However, due to response and sampling bias, levels of parenting stress in asthmatic mothers may be underreported in our sample.]]> Wed 13 Mar 2024 08:01:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50107 Wed 12 Jul 2023 13:43:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50859 Wed 09 Aug 2023 10:13:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54622 Wed 06 Mar 2024 10:53:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54624 Wed 06 Mar 2024 10:53:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49079 Wed 03 May 2023 16:14:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44806 Wed 01 May 2024 12:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49760 Tue 30 May 2023 18:39:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55205 Tue 30 Apr 2024 10:50:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46724 Tue 29 Nov 2022 11:27:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46634 p < 0.05) and controls. In bronchiectasis and COPD, lower levels/better patterns of ST accumulation, as well as higher LIPA volume were associated with better clinical characteristics. These associations may be mediated by airflow limitation. Conclusions: The discordance between engagement in ST volume versus ST patterns highlights the importance of accounting for both these different yet complementary metrics. ST and LIPA are low-intensity activities associated with important clinical characteristics in people with chronic respiratory diseases. Trial registration: Not applicable.]]> Tue 29 Nov 2022 10:26:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54427 Tue 27 Feb 2024 13:53:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43470 4 months (75% mepolizumab; 25% omalizumab, and 25% macrolide) were recruited. Qualitative semi structured interviews were conducted, with interviews thematically analysed. Results: Participants’ mean (SD) age was 59.5 (15.3) years, and 50% were male. Participants reported 4.5 (2.3) exacerbations in the past year. Asthma Control Questionnaire score was 2.0 (1.4). The monoclonal add-on therapies had been prescribed for a median (IQR) of 12.5 (7.0, 24.0) months. Experience was captured in four emergent themes: “Life is just easier” provided an overall message that the add-on therapy made the participants’ life easier in terms of increasing participation, levelling out symptoms, providing more energy and reducing healthcare use. “Prednisone: A necessary evil” was discussed, particularly in terms of dose and dependence and damaging side effects. The theme “worry and hope for the future” referenced treatment non-response or cessation of effect which was discussed by some participants. Finally, “holistic care” was centred on the sentiment that the participant’s asthma management and overall health were not related to one aspect or medication alone. Conclusion: Patients with severe asthma experience vast improvements in quality-of-life and life participation with add-on therapies, but there remains a significant burden related to oral corticosteroids and incomplete treatment responses. Addressing this residual burden is an important area for future research.]]> Tue 20 Sep 2022 10:13:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54370 Tue 20 Feb 2024 19:58:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51001 Tue 15 Aug 2023 12:06:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52770 Tue 14 Nov 2023 15:04:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49105 Tue 14 Nov 2023 14:40:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54571 Tue 14 May 2024 14:15:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47084 Tue 13 Dec 2022 16:35:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51598 Tue 12 Sep 2023 12:25:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53621 Tue 12 Dec 2023 15:19:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44349 Tue 11 Oct 2022 19:35:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51437 Tue 05 Sep 2023 17:56:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48952 Tue 02 May 2023 11:43:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53499 Thu 30 Nov 2023 15:57:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54560 Thu 29 Feb 2024 10:27:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40658 Thu 28 Jul 2022 12:42:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39670 Thu 28 Jul 2022 08:10:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45375 Thu 27 Oct 2022 16:54:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45364 Thu 27 Oct 2022 15:35:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46415 Thu 24 Nov 2022 13:56:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39023 Thu 21 Apr 2022 09:51:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48885 10 years: 65% vs. 33%, p < 0.002). QoL was impaired in both groups, but there were no significant differences between severe asthma and COPD carers in either of the SF-12 component scores. The HADS scores revealed no difference between groups. Compared to severe asthma carers, COPD carers had significantly greater needs for: ‘having time for self’ (33% vs. 13%, p = 0.006), ‘equipment to help care for relative’ (33% vs. 13%, p = 0.006), ‘practical help in the home’ (35% vs. 18%, p = 0.006) and ‘getting a break from caring overnight’ (21% vs. 6%, p = 0.023). Conclusion: QoL is impaired in carers of people with severe asthma to a similar degree of COPD carers and other debilitating diseases like cancer. These novel data highlight the support needs of severe asthma carers and identifies areas where tailored support is needed to reduce their substantial carer burden.]]> Thu 20 Apr 2023 09:27:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49460 1000 mg prednisolone-equivalent cumulatively are likely to have serious side effects and adverse outcomes. Patient perspectives emphasize the detrimental impacts of OCS-related side effects such as weight gain, insomnia, mood disturbances and skin changes. Improvements in asthma control and prevention of exacerbations can be achieved by improved inhaler technique, adherence to therapy, asthma education, smoking cessation, multidisciplinary review, optimized medications and other strategies. Recently, add-on therapies including novel biological agents and macrolide antibiotics have demonstrated reductions in OCS requirements. Harm reduction may also be achieved through identification and mitigation of predictable adverse effects. OCS stewardship should entail greater awareness of appropriate indications for OCS prescription, risk–benefits of OCS medications, side effects, effective add-on therapies and multidisciplinary review. If implemented, OCS stewardship can ensure that clinicians and patients with asthma are aware that OCS should not be used lightly, while providing reassurance that asthma can be controlled in most people without frequent use of OCS.]]> Thu 18 May 2023 12:40:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48386 2-agonist add-ons (54.1 vs 39.8%), and experienced significantly (P < .001) more exacerbations per year (median, 3 vs 2/y), worse asthma control, and worse lung function (% predicted postbronchodilator FEV1/forced vital capacity, 0.69 vs 0.72) versus nonreferred patients. Confirmed patients with severe asthma (ie, UK patients in the International Severe Asthma Registry) were younger (51 vs 65 years; P < .001), and significantly (P < .001) more likely to have uncontrolled asthma (91.4% vs 62.5%), a higher exacerbation rate (4/y [initial assessment] vs 3/y), use inhaled corticosteroid/long-acting β₂-agonist add-ons (67.7% vs 54.1%), and have nasal polyposis (24.2% vs 6.8) than referred patients with PSA. Conclusions: Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.]]> Thu 16 Mar 2023 08:32:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49306 Thu 11 May 2023 14:32:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50895 Thu 10 Aug 2023 10:29:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49876 3 mg/L), and depression. In both trials, TT treatment led to a large, significant improvement in HRQOL compared with usual care (Cohen's d = 1.19; P < .001). Receiving a statin for systemic inflammation and oral corticosteroid for eosinophilic airway inflammation was associated with the largest HRQOL improvements. Treatments for exercise intolerance, anxiety, and obesity were associated with smaller improvements in HRQOL. Conclusions: This study contributes to identifying clinically impactful TTs by showing that TTs across pulmonary, extrapulmonary, and behavioral domains were associated with HRQOL impairment and treatment response.]]> Thu 08 Jun 2023 15:21:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40293 Thu 07 Jul 2022 15:11:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47317 Thu 06 Jul 2023 13:59:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52233 Thu 05 Oct 2023 11:40:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52202 Thu 05 Oct 2023 10:09:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46835 Thu 01 Dec 2022 14:54:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37810 Mon 31 Jan 2022 15:14:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38401 Mon 29 Jan 2024 17:48:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47276 Mon 27 Mar 2023 13:58:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49544 Mon 22 May 2023 08:45:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53946 Mon 22 Jan 2024 16:57:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53947 Mon 22 Jan 2024 16:56:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46104 adj = 9.6, 95% CI: 1.8–50.1) and the presence of Haemophilus influenzae in the BAL (OR_adj = 5.1, 95% CI: 1.4–19.1). Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. A significant BDR (FEV₁ improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen-specific IgE (OR_adj = 14.8, 95% CI: 2.2–100.8) at baseline and bronchomalacia (OR_adj = 5.9, 95% CI: 1.2–29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range. Conclusion: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.]]> Mon 21 Nov 2022 09:17:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46276 Mon 14 Nov 2022 15:31:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46274 Mon 14 Nov 2022 15:28:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46232 Mon 14 Nov 2022 12:33:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46221 Mon 14 Nov 2022 12:04:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52317 Mon 09 Oct 2023 10:23:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41043 p=.001), use of inhaled corticosteroids (68.2% and RR 2.17, 95% CI 1.19-3.99, p=.001) and short-acting β-agonists in the last 12 months (95.2% and RR 1.49, 95% CI 1.17-1.89, p=.001), as compared to those with RV negative bronchiolitis and no maternal asthma history. More children in this group had an abnormal airway resistance (33.3% and adjusted risk ratio [aRR] 3.11, 95% CI 1.03-9.47, p=.045) and reactance (27.8% and aRR 2.11, 95% CI 1.06-4.26, p=.035) at 5 Hz, as compared to those with RV negative bronchiolitis and no maternal asthma history. Conclusion: Hospitalization for RV positive bronchiolitis in early life combined with a history of maternal asthma identifies a subgroup of children with a high asthma burden while participants with only one of the two risk factors had intermediate risk for asthma.]]> Mon 08 Aug 2022 14:50:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55058 Mon 08 Apr 2024 09:43:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47886 Mon 06 Feb 2023 11:33:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48632 Fri 24 Mar 2023 10:57:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51908 50%. Computed tomography of the larynx is a new technology with potential for swift diagnosis that requires validation in clinical pathways. Disease pathogenesis and multimorbidity interactions are complex reflecting a multi-factorial, complex condition, with no single overarching disease mechanism. Currently there is no evidence-based standard of care since randomized trials for treatment are non-existent. Recent multidisciplinary models of care need to be clearly articulated and prospectively investigated. Patient impact and healthcare utilization can be formidable but have largely escaped inquiry and patient perspectives have not been explored. Roundtable participants expressed optimism as collective understanding of this complex condition evolves. The Melbourne VCD/ILO Roundtable 2022 identified clear priorities and future directions for this impactful condition.]]> Fri 22 Sep 2023 10:25:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52682 Fri 20 Oct 2023 09:44:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53104 Fri 17 Nov 2023 11:38:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53110 2-agonist. This study shows that, in response to the limitation of a stepwise approach to therapy, treatable traits is a new strategy where patients are individually assessed for a specified set of treatable problems, and an individualized treatment program is developed and implemented based on this multidimensional assessment, especially for difficult-to-treat asthma.]]> Fri 17 Nov 2023 11:25:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55351 r > –0.19; P ≤ .03). Conclusions: Adults with severe asthma have worse core function than their control counterparts, independent of sex. Furthermore, as core function decreases, breathing symptoms increase.]]> Fri 17 May 2024 15:58:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55350 Fri 17 May 2024 15:57:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55342 30 mg/d; percent-predicted forced expiratory volume in 1 second [ppFEV1]: <50% to ≥80%). Results: Percentage of biologic responders (ie, those with a category improvement pre- to post-biologic) varied by domain and increased with greater pre-biologic impairment, increasing from 70.2% to 90.0% for exacerbation rate, 46.3% to 52.3% for asthma control, 31.1% to 58.5% for LTOCS daily dose, and 35.8% to 50.6% for ppFEV1. The proportion of patients having improvement post-biologic tended to be greater for anti–IL-5/5R compared with for anti-IgE for exacerbation, asthma control, and ppFEV1 domains, irrespective of pre-biologic impairment. Conclusion: Our results provide realistic outcome-specific post-biologic expectations for both physicians and patients, will be foundational to inform future work on a multidimensional approach to define and assess biologic responders and response, and may enhance appropriate patient selection for biologic therapies. Trial Registration: The ISAR database has ethical approval from the Anonymous Data Ethics Protocols and Transparency (ADEPT) committee (ADEPT0218) and is registered with the European Union Electronic Register of Post-Authorization studies (ENCEPP/DSPP/23720). The study was designed, implemented, and reported in compliance with the European Network Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) Code of Conduct (EUPAS38288) and with all applicable local and international laws and regulation, and registered with ENCEPP (https://www.encepp.eu/encepp/viewResource.htm?id=38289). Governance was provided by ADEPT (registration number: ADEPT1220).]]> Fri 17 May 2024 15:51:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44511 Fri 14 Oct 2022 09:11:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44479 Fri 14 Oct 2022 08:50:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47321 Fri 13 Jan 2023 11:06:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49427 Fri 12 May 2023 15:16:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49414 Fri 12 May 2023 15:02:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46066 Fri 11 Nov 2022 14:45:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46047 Fri 11 Nov 2022 14:11:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46108 Fri 11 Nov 2022 13:50:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38377 Fri 10 Sep 2021 12:38:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51535 Fri 08 Sep 2023 12:31:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49200 Fri 05 May 2023 15:58:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55056 Fri 05 Apr 2024 14:28:53 AEDT ]]>